Zoledronic Acid, alendronate, and risedronate reduce vertebral, nonvertebral, and hip fracture
This report has been verified
by one or more authors of the
original publication.
Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses
Osteoporos Int. 2016 Nov;27(11):3289-330036 randomized controlled trials were included in this network meta-analysis to evaluate the comparative efficacy of different bisphosphonates in the management of osteoporosis. Nine different bisphosphonates were assessed in the included studies, with direct and indirect comparisons evaluated for vertebral fracture, nonvertebral fracture, hip fracture, wrist fracture, and any fracture. Zoledronic acid seemed to be the most effective bisphosphonate for reducing the risk of fracture for vertebral fracture, nonvertebral fracture, and any fracture. While zoledronic acid or alendronate seemed to be the most effective for preventing hip fracture.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
